Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 31 Jan 2023
Reneo Pharmaceuticals receives fast track designation from the FDA for mavodelpar (REN001) in a genotype of long-chain fatty acid oxidation disorder
31 January 2023 - Reneo Pharmaceuticals today announced that the US FDA has granted mavodelpar (REN001) fast track designation for long ...
Posted by Michael Wonder on 31 Jan 2023
Amjevita (adalimumab-atto), first biosimilar to Humira, now available in the United States
31 January 2023 - Four years of real world experience in more than 300,000 patients and over 60 countries. ...
Posted by Michael Wonder on 31 Jan 2023
Call for Enhertu to be registered on Pharmaceutical Benefits Scheme
31 January 2023 - Sarah Lee has been forced to use her super and life insurance to pay for the treatment. ...
Posted by Michael Wonder on 31 Jan 2023
International price comparison of medicines (2022)
31 January 2023 - The price of prescription drugs in Sweden has fallen compared to other countries since 2014 and is ...
Posted by Michael Wonder on 31 Jan 2023
Association between pre-approval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway
27 January 2023 - The accelerated approval pathway allows the US FDA to approve drugs that demonstrate an effect on a ...
Posted by Michael Wonder on 31 Jan 2023
Distribution markups and taxes for prescription pharmaceuticals: do we see the complete picture of the pharmaceutical price?
30 January 2023 - An analysis presented at the ISPOR Europe 2021 conference highlighted considerable variability across countries in how much ...
Posted by Michael Wonder on 31 Jan 2023
FDA may not always require post-approval trials to be enrolled before accelerated approvals
30 January 2023 - A FDa official on Monday gave more clues for how the agency plans to wield new authority ...
Posted by Michael Wonder on 31 Jan 2023
Options for a reformed Prostheses List pre-listing assessment framework and governance structure
31 January 2023 - This report provides a framework and proposes options for governance that would align the Prostheses List processes ...
Posted by Michael Wonder on 31 Jan 2023
Medicare drug price negotiation in the United States: implications and unanswered questions
8 December 2022 - The United States is a relatively free pricing market for pharmaceutical manufacturers to set list prices at ...
Posted by Michael Wonder on 30 Jan 2023
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor pimicotinib (ABSK021)
30 January 2023 - Abbisko Therapeutics today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted breakthrough therapy designation ...
Posted by Michael Wonder on 30 Jan 2023
Amazon’s bold $5 prescription drug program is the future of pharmacy
28 January 2023 - Amazon is taking yet another bold step into the world of health care, further solidifying its powerful ...
Posted by Michael Wonder on 30 Jan 2023
Why drug makers have raised prices on nearly 1,000 drugs so far this year
30 January 2023 - With pharmaceutical companies hiking prices on nearly 1,000 drugs in January, some consumers might experience sticker ...
Posted by Michael Wonder on 30 Jan 2023
US law makers call on Biden Administration to lower the price of enzalutamide
27 January 2023 - US Senator Elizabeth Warren, a Democrat from Massachusetts, and nearly two dozen other lawmakers are demanding to ...
Posted by Michael Wonder on 30 Jan 2023
Alpha Biopharma submits new drug application for zorifertinib, a next generation EGFR-TKI to treat EGFR mutated NSCLC patients with CNS metastases
30 January 2023 - Alpha Biopharma announces that the Center for Drug Evaluation of the NMPA has accepted its new drug ...
Posted by Michael Wonder on 30 Jan 2023
Junshi Biosciences announces approval for marketing of VV116 in China
30 January 2023 - Shanghai Junshi Biosciences announced today that the NMPA has conducted urgent review and approval under special examination ...